We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

73 hedge funds and large institutions have $403M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

56% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 16

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

24% more funds holding

Funds holding: 59 → 73 (+14)

24% less capital invested

Capital invested by funds: $533M → $403M (-$131M)

Holders
73
Holders Change
+14
Holders Change %
+23.73%
% of All Funds
1.61%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
18
Increased
25
Reduced
16
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Aquilo Capital Management
California
+$17.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$16.3M
3
PS
Peter Svennilson
+$14.7M
4
Marshall Wace
Marshall Wace
United Kingdom
+$3.73M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.73M

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$1.76M
2
OAM
Oxford Asset Management
United Kingdom
-$1.3M
3
BlackRock
BlackRock
New York
-$927K
4
Morgan Stanley
Morgan Stanley
New York
-$700K
5
Goldman Sachs
Goldman Sachs
New York
-$685K
Name Holding Trade Value Shares
Change 		Change in
Stake
PS
1
Peter Svennilson
$214M +$14.7M +902,315 +5%
RCP
2
Rho Capital Partners
New York
$46.4M – – –
BlackRock
3
BlackRock
New York
$27.8M -$927K -56,780 -2%
GA
4
Greenspring Associates
Maryland
$19.4M – – –
ACM
5
Aquilo Capital Management
California
$12.9M +$17.1M +1,047,184 New
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$12.3M +$16.3M +996,295 New
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$11.5M -$28K -1,716 -0.2%
Vanguard Group
8
Vanguard Group
Pennsylvania
$5.84M +$233K +14,298 +3%
State Street
9
State Street
Massachusetts
$5.66M +$1.34M +82,379 +22%
CS
10
Candriam SCA
Luxembourg
$4.37M – – –
RSCM
11
Rock Springs Capital Management
Maryland
$4.33M – – –
JRP
12
Jasper Ridge Partners
California
$3.81M +$28.6K +1,750 +0.6%
Northern Trust
13
Northern Trust
Illinois
$3.26M +$35.3K +2,163 +0.8%
BBA
14
Baker Bros. Advisors
New York
$3.08M – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$3M -$683K -41,823 -15%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.89M +$779K +47,697 +25%
Marshall Wace
17
Marshall Wace
United Kingdom
$2.82M +$3.73M +228,551 New
Citadel Advisors
18
Citadel Advisors
Florida
$2.53M +$2.73M +167,388 +446%
Renaissance Technologies
19
Renaissance Technologies
New York
$1.84M +$2.43M +149,100 New
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$1.7M +$2.25M +137,964 New
N
21
Nuveen
North Carolina
$1.41M -$1.76M -108,031 -49%
Millennium Management
22
Millennium Management
New York
$1.17M +$435K +26,647 +39%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.01M +$385K +23,567 +40%
Charles Schwab
24
Charles Schwab
California
$996K +$27K +1,655 +2%
Victory Capital Management
25
Victory Capital Management
Texas
$974K +$583K +35,700 +82%
1
2 3 4

NGM Hedge Fund Activity: Q1 2020 in Review

73 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2020, worth a combined $403M — down 24% from $533M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new NGM positions and 4 closed out — a net gain of 14 holders — while 25 added to existing stakes and 16 trimmed.

The largest buyer was Aquilo Capital Management, opening a new position worth an estimated $17.1M. The largest seller was Nuveen, cutting an estimated $1.76M.

  • 73 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2020, up from 59 in Q4 2019.
  • Funds reported $403M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2020, down 24% quarter-over-quarter.
  • 18 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2020 and 4 closed out, a net change of +14 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Aquilo Capital Management, an estimated $17.1M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2020 was Nuveen, an estimated $1.76M sold.

Based on aggregated 13F filings for Q1 2020.